AlphaVax, Inc.-Product Pipeline Review-2015

AlphaVax, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06954CDB
  • |
  • Pages: 34
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

AlphaVax, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'AlphaVax, Inc.-Product Pipeline Review-2015', provides an overview of the AlphaVax, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AlphaVax, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of AlphaVax, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of AlphaVax, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the AlphaVax, Inc.'s pipeline products

Reasons To Buy

Evaluate AlphaVax, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of AlphaVax, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the AlphaVax, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of AlphaVax, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of AlphaVax, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of AlphaVax, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

AlphaVax, Inc. Snapshot 5

AlphaVax, Inc. Overview 5

Key Information 5

Key Facts 5

AlphaVax, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

AlphaVax, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

AlphaVax, Inc.-Pipeline Products Glance 11

AlphaVax, Inc.-Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

AlphaVax, Inc.-Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

AlphaVax, Inc.-Drug Profiles 13

AVX-502 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

AVX-701 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

AVX-101 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

AVX-601 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

AVX-901 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

respiratory syncytial virus vaccine 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

botulinum vaccine 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ebola and marburg vaccine 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

equine encephalitis vaccine 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

herpes simplex virus [serotype 2] vaccine 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

HIV (multivalent) vaccine 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

influenza [strain H5N1, H1N1] vaccine 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

severe acute respiratory syndrome vaccine 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

smallpox vaccine 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

AlphaVax, Inc.-Pipeline Analysis 28

AlphaVax, Inc.-Pipeline Products by Target 28

AlphaVax, Inc.-Pipeline Products by Route of Administration 29

AlphaVax, Inc.-Pipeline Products by Molecule Type 30

AlphaVax, Inc.-Recent Pipeline Updates 31

AlphaVax, Inc.-Locations And Subsidiaries 32

Head Office 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

AlphaVax, Inc., Key Information 5

AlphaVax, Inc., Key Facts 5

AlphaVax, Inc.-Pipeline by Indication, 2015 8

AlphaVax, Inc.-Pipeline by Stage of Development, 2015 9

AlphaVax, Inc.-Monotherapy Products in Pipeline, 2015 10

AlphaVax, Inc.-Phase I, 2015 11

AlphaVax, Inc.-Preclinical, 2015 12

AlphaVax, Inc.-Pipeline by Target, 2015 28

AlphaVax, Inc.-Pipeline by Route of Administration, 2015 29

AlphaVax, Inc.-Pipeline by Molecule Type, 2015 30

AlphaVax, Inc.-Recent Pipeline Updates, 2015 31

List of Figures

AlphaVax, Inc.-Pipeline by Top 10 Indication, 2015 7

AlphaVax, Inc.-Pipeline by Stage of Development, 2015 9

AlphaVax, Inc.-Monotherapy Products in Pipeline, 2015 10

AlphaVax, Inc.-Pipeline by Top 10 Target, 2015 28

AlphaVax, Inc.-Pipeline by Top 10 Route of Administration, 2015 29

AlphaVax, Inc.-Pipeline by Top 10 Molecule Type, 2015 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of AlphaVax, Inc.; AlphaVax, Inc. - Key Therapeutics; AlphaVax, Inc. - Pipeline Overview and Promising Molecules; AlphaVax, Inc. - News; AlphaVax, Inc. - Latest Updates; AlphaVax, Inc. - Pipeline; AlphaVax, Inc. - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 107340
Site License
USD 3000 INR 214680
Corporate User License
USD 4500 INR 322020



I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]